Compare Stocks: PLX, BBOT, ALLO, and MNPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.99 -1.5%	$1.99	$1.04 ▼ $4.46	$687.53M	0.48	7.98 million shs	1.88 million shs
BBOT BridgeBio Oncology Therapeutics	$8.61 -1.5%	$8.61	$7.00 ▼ $14.87	$690.26M	0.35	354,489 shs	259,458 shs
MNPR Monopar Therapeutics	$109.97 -1.7%	$106.44	$32.77 ▼ $124.82	$737.90M	1.47	219,283 shs	74,094 shs
PLX Protalix BioTherapeutics	$2.59 +2.0%	$2.36	$1.52 ▼ $3.19	$208.68M	0.02	927,166 shs	309,558 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-3.35%	+7.45%	-6.05%	+78.76%
BBOT BridgeBio Oncology Therapeutics	0.00%	-3.74%	+8.03%	+2.22%	+873,999,900.00%
MNPR Monopar Therapeutics	0.00%	+3.87%	+3.27%	+73.74%	+227.64%
PLX Protalix BioTherapeutics	0.00%	+6.72%	+7.17%	+23.30%	+63.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.99 -1.5%	$1.99	$1.04 ▼ $4.46	$687.53M	0.48	7.98 million shs	1.88 million shs
BBOT BridgeBio Oncology Therapeutics	$8.61 -1.5%	$8.61	$7.00 ▼ $14.87	$690.26M	0.35	354,489 shs	259,458 shs
MNPR Monopar Therapeutics	$109.97 -1.7%	$106.44	$32.77 ▼ $124.82	$737.90M	1.47	219,283 shs	74,094 shs
PLX Protalix BioTherapeutics	$2.59 +2.0%	$2.36	$1.52 ▼ $3.19	$208.68M	0.02	927,166 shs	309,558 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-3.35%	+7.45%	-6.05%	+78.76%
BBOT BridgeBio Oncology Therapeutics	0.00%	-3.74%	+8.03%	+2.22%	+873,999,900.00%
MNPR Monopar Therapeutics	0.00%	+3.87%	+3.27%	+73.74%	+227.64%
PLX Protalix BioTherapeutics	0.00%	+6.72%	+7.17%	+23.30%	+63.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.30	317.09% Upside
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.40	183.39% Upside
MNPR Monopar Therapeutics	2.86	Moderate Buy	$118.67	7.91% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	363.32% Upside

Current Analyst Ratings Breakdown

Latest PLX, BBOT, ALLO, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	MNPR Monopar Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$130.00
8/17/2026	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$6.00
8/14/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$27.00 ➝ $25.00
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00
8/13/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$109.00 ➝ $119.00
8/13/2026	MNPR Monopar Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	MNPR Monopar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$117.00 ➝ $133.00
7/29/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/23/2026	MNPR Monopar Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$125.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	34,376.26	N/A	N/A	$1.30 per share	1.53
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$5.14 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
PLX Protalix BioTherapeutics	$80.62M	2.59	$0.15 per share	17.80	$0.47 per share	5.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.76	N/A	N/A	N/A	N/A	-46.90%	-42.17%	N/A
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.23	N/A	8.35	N/A	-21.03%	-30.89%	-11.74%	N/A

Latest PLX, BBOT, ALLO, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	10.72	10.72
BBOT BridgeBio Oncology Therapeutics	N/A	4.69	4.69
MNPR Monopar Therapeutics	N/A	33.56	33.56
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
BBOT BridgeBio Oncology Therapeutics	54.89%
MNPR Monopar Therapeutics	1.83%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
BBOT BridgeBio Oncology Therapeutics	24.40%
MNPR Monopar Therapeutics	9.70%
PLX Protalix BioTherapeutics	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	345.49 million	299.89 million	Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.17 million	60.61 million	N/A
MNPR Monopar Therapeutics	10	6.71 million	6.06 million	Not Optionable
PLX Protalix BioTherapeutics	200	80.57 million	69.00 million	Optionable

PLX, BBOT, ALLO, and MNPR Headlines

Recent News About These Companies

Zacks Research Brokers Reduce Earnings Estimates for PLX

August 22, 2026 | americanbankingnews.com

Zacks Research Issues Pessimistic Outlook for PLX Earnings

August 20, 2026 | marketbeat.com

Protalix (PLX) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs

August 16, 2026 | kalkinemedia.comK

PLX: Elfabrio estimates up

August 13, 2026 | msn.com

Protalix signals Elfabrio path to 15% to 20% Fabry market share by 2031, backed by Europe every-4-weeks approval

August 12, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

August 12, 2026 | finanznachrichten.de

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

August 12, 2026 | prnewswire.com

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

August 5, 2026 | prnewswire.com

Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary

May 15, 2026 | finance.yahoo.com

PLX: Chiesi Milestone Received

May 14, 2026 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript

May 14, 2026 | insidermonkey.com

Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call

May 14, 2026 | uk.finance.yahoo.com

Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...

May 14, 2026 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

May 13, 2026 | seekingalpha.com

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 13, 2026 | prnewswire.com

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

May 6, 2026 | prnewswire.com

Protalix: Elfabrio Struggles Against Oral Competition

April 15, 2026 | seekingalpha.com

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

March 24, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

March 18, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PLX, BBOT, ALLO, and MNPR Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.99 -0.03 (-1.49%)

As of 12:27 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$8.61 -0.13 (-1.49%)

As of 12:26 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Monopar Therapeutics NASDAQ:MNPR

$109.97 -1.92 (-1.72%)

As of 12:24 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Protalix BioTherapeutics NYSE:PLX

$2.59 +0.05 (+1.97%)

As of 12:28 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, BBOT, ALLO, and MNPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, BBOT, ALLO, and MNPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, BBOT, ALLO, and MNPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLX, BBOT, ALLO, and MNPR Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Monopar Therapeutics NASDAQ:MNPR

Protalix BioTherapeutics NYSE:PLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, BBOT, ALLO, and MNPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, BBOT, ALLO, and MNPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, BBOT, ALLO, and MNPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLX, BBOT, ALLO, and MNPR Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Monopar Therapeutics NASDAQ:MNPR

Protalix BioTherapeutics NYSE:PLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools